Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;5(2):213-220.
doi: 10.1007/s41030-019-00101-9. Epub 2019 Oct 21.

Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study

Nadzeya Marozkina  1 , Joe Zein  1 , Mark D DeBoer  2 , Laurie Logan  3 , Laura Veri  3 , Kristie Ross  1   3 , Benjamin Gaston  4   5
Affiliations

Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study

Nadzeya Marozkina et al. Pulm Ther. 2019 Dec.

Abstract

Introduction: Among individuals with severe asthma, FEV1 is low in individuals with low dehydroepiandrosterone (DHEA) sulfate (DHEAS) levels. In the Severe Asthma Research Program (SARP), no women with DHEAS > 200 μg/dL had an FEV1 < 60% predicted. DHEA has benefited patients with COPD and pulmonary hypertension in small trials. Therefore, we hypothesized that DHEA supplementation may improve FEV1 in asthmatic women with low DHEAS.

Methods: Premenopausal, nonsmoking, otherwise healthy women, 18-50 years old, with mild or moderate asthma and baseline FEV1 > 60% predicted received 100 mg DHEA orally every 12 h for 2 weeks. Spirometry and DHEAS were measured at the initial visit and 2 weeks later, after completion of DHEA treatment. Based on our previous work, the primary outcome variable for this pilot study was post-albuterol spirometry in the low-DHEAS group. Subjects also continued their other routine asthma management.

Results: Serum DHEAS increased with DHEA treatment in women with starting DHEAS < 200 µg/dL: this increase was from 71 ± 23 to 725 ± 295 µg/dL (n = 10; p = 0.0001). The increase in the high-DHEAS group was smaller. Post-albuterol FEV1 increased by 51 mL, from 3.026 ± 0.5 to 3.077 ± 0.49 L (n = 10; p = 0.034 by paired t test, significant after Bonferroni), in women with low DHEAS. In the high-DHEAS group (baseline DHEAS ≥ 200 µg/dl), post-albuterol FEV1 did not change significantly (n = 3, p = NS). Three subjects were excluded: one had comorbid COPD, one could not perform spirometry, and one did not take the DHEA. There were no adverse effects of DHEA treatment in this trial.

Conclusions: Endocrine treatments (corticosteroids) are a mainstay of anti-inflammatory management for moderate and severe asthma. Their use has improved asthma outcomes. Androgens also reduce airway inflammation and promote airway smooth muscle relaxation, but are rarely used clinically for asthma treatment. Our results suggest that the over-the-counter steroid DHEA may improve lung function in asthma outcomes among women with DHEAS < 200 ug/dL.

Keywords: Asthma; Dehydroepiandrosterone (DHEA); Lung function.

PubMed Disclaimer

References

    1. Centers for Disease Control National Health Interview Survey, 2012. Source: summary Health Statistics for U.S. Adults: National Health Interview Survey. 2012. http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed 15 Oct 2019.
    1. Centers for Disease Control National Health Interview Survey, 2010, Source: National Ambulatory Medical Care Survey. 2010:Summary Tables, table 13. http://www.cdc.gov/nchs/fastats/asthma.htm.
    1. Centers for Disease Control and Prevention, Vital Signs (monthly statistical report). 2011. https://www.cdc.gov/vitalsigns/pdf/2011-05-vitalsigns.pdf. Accessed 15 Oct 2019.
    1. Slejko JF, Ghushchyan VH, Sucher B, Globe DR, Lin SL, Globe G, et al. Asthma control in the United States, 2008-2010: indicators of poor asthma control. J Allergy Clin Immunol. 2014;133(6):1579–1587. - PubMed
    1. Morbidity and Mortality Report. National Center for Health Statistics (NCHS), U.S. CDC. 2003.